Bianchi Arnaud, Moulin David, Sebillaud Sylvie, Koufany Meriem, Galteau Marie-Madeleine, Netter Patrick, Terlain Bernard, Jouzeau Jean-Yves
Laboratoire de Physiopathologie et Pharmacologie Articulaires, UMR 7561 CNRS-UHP, 54505 Vandoeuvre-lès-Nancy, France.
Arthritis Res Ther. 2005;7(6):R1325-37. doi: 10.1186/ar1830. Epub 2005 Sep 22.
Microsomal prostaglandin E synthase (mPGES)-1 is a newly identified inducible enzyme of the arachidonic acid cascade with a key function in prostaglandin (PG)E2 synthesis. We investigated the kinetics of inducible cyclo-oxygenase (COX)-2 and mPGES-1 expression with respect to the production of 6-keto-PGF1alpha and PGE2 in rat chondrocytes stimulated with 10 ng/ml IL-1beta, and compared their modulation by peroxisome-proliferator-activated receptor (PPAR)gamma agonists. Real-time PCR analysis showed that IL-1beta induced COX-2 expression maximally (37-fold) at 12 hours and mPGES-1 expression maximally (68-fold) at 24 hours. Levels of 6-keto-PGF1alpha and PGE2 peaked 24 hours after stimulation with IL-1beta; the induction of PGE2 was greater (11-fold versus 70-fold, respectively). The cyclopentenone 15-deoxy-Delta12,14prostaglandin J2 (15d-PGJ2) decreased prostaglandin synthesis in a dose-dependent manner (0.1 to 10 microM), with more potency on PGE2 level than on 6-keto-PGF1alpha level (-90% versus -66% at 10 microM). A high dose of 15d-PGJ2 partly decreased COX-2 expression but decreased mPGES-1 expression almost completely at both the mRNA and protein levels. Rosiglitazone was poorly effective on these parameters even at 10 microM. Inhibitory effects of 10 microM 15d-PGJ2 were neither reduced by PPARgamma blockade with GW-9662 nor enhanced by PPARgamma overexpression, supporting a PPARgamma-independent mechanism. EMSA and TransAM analyses demonstrated that mutated IkappaBalpha almost completely suppressed the stimulating effect of IL-1beta on mPGES-1 expression and PGE2 production, whereas 15d-PGJ2 inhibited NF-kappaB transactivation. These data demonstrate the following in IL-1-stimulated rat chondrocytes: first, mPGES-1 is rate limiting for PGE2 synthesis; second, activation of the prostaglandin cascade requires NF-kappaB activation; third, 15d-PGJ2 strongly inhibits the synthesis of prostaglandins, in contrast with rosiglitazone; fourth, inhibition by 15d-PGJ2 occurs independently of PPARgamma through inhibition of the NF-kappaB pathway; fifth, mPGES-1 is the main target of 15d-PGJ2.
微粒体前列腺素E合酶(mPGES)-1是一种新发现的花生四烯酸级联反应中的诱导酶,在前列腺素(PG)E2合成中起关键作用。我们研究了在10 ng/ml白细胞介素(IL)-1β刺激的大鼠软骨细胞中,诱导型环氧化酶(COX)-2和mPGES-1表达动力学与6-酮-前列腺素F1α和PGE2产生的关系,并比较了过氧化物酶体增殖物激活受体(PPAR)γ激动剂对它们的调节作用。实时聚合酶链反应(PCR)分析表明,IL-1β在12小时时最大程度地诱导COX-2表达(37倍),在24小时时最大程度地诱导mPGES-1表达(68倍)。6-酮-前列腺素F1α和PGE2水平在IL-1β刺激后24小时达到峰值;PGE2的诱导作用更强(分别为11倍和70倍)。环戊烯酮15-脱氧-Δ12,14-前列腺素J2(15d-PGJ2)以剂量依赖方式(0.1至10 μM)降低前列腺素合成,对PGE2水平的作用比对6-酮-前列腺素F1α水平的作用更强(10 μM时分别为-90%和-66%)。高剂量的15d-PGJ2部分降低COX-2表达,但在mRNA和蛋白质水平上几乎完全降低mPGES-1表达。罗格列酮即使在10 μM时对这些参数也效果不佳。10 μM 15d-PGJ2的抑制作用既不被GW-9662阻断PPARγ所降低,也不被PPARγ过表达所增强,支持一种不依赖PPARγ的机制。电泳迁移率变动分析(EMSA)和转录激活分析(TransAM)表明,突变的IκBα几乎完全抑制IL-1β对mPGES-1表达和PGE2产生的刺激作用,而15d-PGJ2抑制核因子κB(NF-κB)的反式激活。这些数据在IL-1刺激的大鼠软骨细胞中表明:第一,mPGES-1是PGE2合成的限速因素;第二,前列腺素级联反应的激活需要NF-κB激活;第三,与罗格列酮相反,15d-PGJ2强烈抑制前列腺素合成;第四,15d-PGJ2通过抑制NF-κB途径独立于PPARγ发挥抑制作用;第五,mPGES-1是15d-PGJ2的主要作用靶点。